{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T13:16:01Z","timestamp":1793711761565,"version":"4.6.1"},"reference-count":43,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.clgc.2023.07.003","type":"journal-article","created":{"date-parts":[[2023,7,7]],"date-time":"2023-07-07T21:24:01Z","timestamp":1688765041000},"page":"594-601.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Cardiovascular Adverse Events Associated With New-Generation Androgen Receptor Pathway Inhibitors (ARPI) for Prostate Cancer: A Disproportionality Analysis Based on the FDA Adverse Event Reporting System (FAERS)"],"prefix":"10.1016","volume":"21","author":[{"given":"Yang","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-min","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Er-hao","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong-jian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cai-xia","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-hao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue-song","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.clgc.2023.07.003_bib0001","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.eururo.2019.08.005","article-title":"Recent global patterns in prostate cancer incidence and mortality rates","volume":"77","author":"Culp","year":"2020","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.clgc.2023.07.003_bib0002","first-page":"209","article-title":"Global cancer statistics 2020: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clinic"},{"issue":"46","key":"10.1016\/j.clgc.2023.07.003_bib0003","doi-asserted-by":"crossref","first-page":"17829","DOI":"10.1074\/jbc.RA118.004846","article-title":"Loss of dihydrotestosterone-inactivation activity promotes prostate cancer castration resistance detectable by functional imaging","volume":"293","author":"Zhu","year":"2018","journal-title":"J Biol Chem"},{"issue":"49","key":"10.1016\/j.clgc.2023.07.003_bib0004","doi-asserted-by":"crossref","first-page":"5501","DOI":"10.1038\/onc.2013.206","article-title":"Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches","volume":"32","author":"Karantanos","year":"2013","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.clgc.2023.07.003_bib0005","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.pharmthera.2013.07.003","article-title":"Androgen receptors in hormone-dependent and castration-resistant prostate cancer","volume":"140","author":"Shafi","year":"2013","journal-title":"Pharmacol Ther"},{"issue":"8","key":"10.1016\/j.clgc.2023.07.003_bib0006","doi-asserted-by":"crossref","first-page":"T19","DOI":"10.1530\/ERC-21-0098","article-title":"Androgen receptor signaling inhibitors: post-chemotherapy, pre-chemotherapy and now in castration-sensitive prostate cancer","volume":"28","author":"Mitsiades","year":"2021","journal-title":"Endocr Relat Cancer"},{"issue":"9","key":"10.1016\/j.clgc.2023.07.003_bib0007","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s11864-019-0668-8","article-title":"Management of metastatic hormone-sensitive prostate cancer (mhspc): an evolving treatment paradigm","volume":"20","author":"Weiner","year":"2019","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.clgc.2023.07.003_bib0008","doi-asserted-by":"crossref","first-page":"801","DOI":"10.3389\/fonc.2019.00801","article-title":"Second-generation antiandrogens: from discovery to standard of care in castration resistant prostate cancer","volume":"9","author":"Rice","year":"2019","journal-title":"Front Oncol"},{"issue":"4","key":"10.1016\/j.clgc.2023.07.003_bib0009","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.eururo.2019.11.021","volume":"77","author":"Matsubara","year":"2020","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.clgc.2023.07.003_bib0010","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa1209096","article-title":"Abiraterone in metastatic prostate cancer without previous chemotherapy","volume":"368","author":"Ryan","year":"2013","journal-title":"N Engl J Med"},{"issue":"32","key":"10.1016\/j.clgc.2023.07.003_bib0011","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1200\/JCO.19.00799","article-title":"Arches: a randomized, phase iii study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer","volume":"37","author":"Armstrong","year":"2019","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clgc.2023.07.003_bib0012","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for metastatic, castration-sensitive prostate cancer","volume":"381","author":"Chi","year":"2019","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.clgc.2023.07.003_bib0013","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa1715546","article-title":"Apalutamide treatment and metastasis-free survival in prostate cancer","volume":"378","author":"Smith","year":"2018","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.clgc.2023.07.003_bib0014","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1097\/JU.0000000000001785","article-title":"Cardiovascular events in men with prostate cancer receiving hormone therapy: an analysis of the fda adverse event reporting system (faers)","volume":"206","author":"Zhang","year":"2021","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.clgc.2023.07.003_bib0015","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s10741-020-09984-2","article-title":"Hormonal prostate cancer therapies and cardiovascular disease: a systematic review","volume":"27","author":"Cereda","year":"2022","journal-title":"Heart Fail Rev"},{"issue":"11","key":"10.1016\/j.clgc.2023.07.003_bib0016","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1200\/JCO.2014.59.1792","article-title":"Risk and timing of cardiovascular disease after androgen-deprivation therapy in men with prostate cancer","volume":"33","author":"O'Farrell","year":"2015","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.clgc.2023.07.003_bib0017","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/S1470-2045(13)70025-1","article-title":"Cardiovascular outcomes in patients with locally advanced and metastatic prostate cancer treated with luteinising-hormone-releasing-hormone agonists or transdermal oestrogen: the randomised, phase 2 mrc patch trial (pr09)","volume":"14","author":"Langley","year":"2013","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.clgc.2023.07.003_bib0018","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1093\/jnci\/djac081","article-title":"Risk of metabolic and cardiovascular adverse events with abiraterone or enzalutamide among men with advanced prostate cancer","volume":"114","author":"Lai","year":"2022","journal-title":"JNCI"},{"issue":"4","key":"10.1016\/j.clgc.2023.07.003_bib0019","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1080\/0284186X.2021.1885058","article-title":"Risk of cardiovascular events in men on abiraterone or enzalutamide combined with gnrh agonists: nation-wide, population-based cohort study in sweden","volume":"60","author":"George","year":"2021","journal-title":"Acta Oncol"},{"key":"10.1016\/j.clgc.2023.07.003_bib0020","first-page":"e71752","article-title":"Characterization and corroboration of safety signals identified from the us food and drug administration adverse event reporting system, 2008-19: cross sectional study","volume":"379","author":"Dhodapkar","year":"2022","journal-title":"Bmj"},{"issue":"2","key":"10.1016\/j.clgc.2023.07.003_bib0021","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1093\/jamia\/ocv063","article-title":"Use of data mining at the food and drug administration","volume":"23","author":"Duggirala","year":"2016","journal-title":"J Am Med Inform Assoc"},{"issue":"1","key":"10.1016\/j.clgc.2023.07.003_bib0022","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1208\/s12248-007-9004-5","article-title":"Informatic tools and approaches in postmarketing pharmacovigilance used by fda","volume":"10","author":"Weaver","year":"2008","journal-title":"The AAPS Journal"},{"key":"10.1016\/j.clgc.2023.07.003_bib0023","doi-asserted-by":"crossref","first-page":"c3529","DOI":"10.1136\/bmj.c3529","article-title":"Interpreting composite outcomes in trials","volume":"341","author":"Freemantle","year":"2010","journal-title":"Bmj"},{"issue":"1","key":"10.1016\/j.clgc.2023.07.003_bib0024","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1186\/s13063-022-06977-4","article-title":"Sample size requirement in trials that use the composite endpoint major adverse cardiovascular events (mace): new insights","volume":"23","author":"Marsal","year":"2022","journal-title":"Trials"},{"issue":"1","key":"10.1016\/j.clgc.2023.07.003_bib0025","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/pds.668","article-title":"A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions","volume":"11","author":"van Puijenbroek","year":"2002","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"10.1016\/j.clgc.2023.07.003_bib0026","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (prrs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"10.1016\/j.clgc.2023.07.003_bib0027","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1177\/0962280211403604","article-title":"Shrinkage observed-to-expected ratios for robust and transparent large-scale pattern discovery","volume":"22","author":"Nor\u00e9n","year":"2013","journal-title":"Stat Methods Med Res"},{"issue":"3","key":"10.1016\/j.clgc.2023.07.003_bib0028","doi-asserted-by":"crossref","first-page":"420","DOI":"10.3390\/healthcare10030420","article-title":"A standardized dataset of a spontaneous adverse event reporting system","volume":"10","author":"Khaleel","year":"2022","journal-title":"Healthcare"},{"key":"10.1016\/j.clgc.2023.07.003_bib0029","doi-asserted-by":"crossref","DOI":"10.1177\/1758834017745819","article-title":"Abiraterone acetate and prednisone in the pre- and post-docetaxel setting for metastatic castration-resistant prostate cancer: a mono-institutional experience focused on cardiovascular events and their impact on clinical outcomes","author":"Cavo","year":"2018","journal-title":"Ther Adv Med Oncol"},{"issue":"1","key":"10.1016\/j.clgc.2023.07.003_bib0030","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.acvd.2019.09.006","article-title":"Heart failure and atrial tachyarrhythmia on abiraterone: a pharmacovigilance study","volume":"113","author":"Bretagne","year":"2020","journal-title":"Arch Cardiovasc Dis"},{"issue":"3","key":"10.1016\/j.clgc.2023.07.003_bib0031","doi-asserted-by":"crossref","first-page":"e645","DOI":"10.1016\/j.clgc.2017.12.007","article-title":"The cardiovascular toxicity of abiraterone and enzalutamide in prostate cancer","volume":"16","author":"Iacovelli","year":"2018","journal-title":"Clin Genitourin Cancer"},{"issue":"5","key":"10.1016\/j.clgc.2023.07.003_bib0032","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100261","article-title":"Risk for stroke and myocardial infarction with abiraterone versus enzalutamide in metastatic prostate cancer patients","volume":"6","author":"Kulkarni","year":"2021","journal-title":"Esmo Open"},{"issue":"5","key":"10.1016\/j.clgc.2023.07.003_bib0033","doi-asserted-by":"crossref","first-page":"e871","DOI":"10.1016\/j.clgc.2019.07.001","article-title":"New hormonal agents in patients with nonmetastatic castration-resistant prostate cancer: meta-analysis of efficacy and safety outcomes","volume":"17","author":"Di Nunno","year":"2019","journal-title":"Clin Genitourin Cancer"},{"issue":"21","key":"10.1016\/j.clgc.2023.07.003_bib0034","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"de Bono","year":"2011","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.clgc.2023.07.003_bib0035","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1097\/COC.0b013e3182a790ce","article-title":"Safety of abiraterone acetate in castration-resistant prostate cancer patients with concomitant cardiovascular risk factors","volume":"38","author":"Procopio","year":"2015","journal-title":"Am J Clinic Oncol"},{"issue":"8","key":"10.1016\/j.clgc.2023.07.003_bib0036","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1002\/pros.22965","article-title":"Safety of enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: expanded access in north america","volume":"75","author":"Joshua","year":"2015","journal-title":"Prostate"},{"issue":"2","key":"10.1016\/j.clgc.2023.07.003_bib0037","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.eururo.2016.07.032","article-title":"Enzalutamide in men with chemotherapy-na\u00efve metastatic castration-resistant prostate cancer: extended analysis of the phase 3 prevail study","volume":"71","author":"Beer","year":"2017","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.clgc.2023.07.003_bib0038","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S1470-2045(15)00518-5","article-title":"Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (terrain): a randomised, double-blind, phase 2 study","volume":"17","author":"Shore","year":"2016","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.clgc.2023.07.003_bib0039","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/s41391-020-00275-3","article-title":"Abiraterone and enzalutamide had different adverse effects on the cardiovascular system: a systematic review with pairwise and network meta-analyses","volume":"24","author":"Lee","year":"2021","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"1","key":"10.1016\/j.clgc.2023.07.003_bib0040","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.urolonc.2020.08.003","article-title":"Androgen receptor inhibitor treatments: cardiovascular adverse events and comorbidity considerations in patients with non-metastatic prostate cancer","volume":"39","author":"Morgans","year":"2021","journal-title":"Urol Oncol"},{"key":"10.1016\/j.clgc.2023.07.003_bib0041","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.urology.2016.06.024","article-title":"Prevalence of cardiovascular disease and osteoporosis during androgen deprivation therapy prescription discordant to eau guidelines: results from a multicenter, cross-sectional analysis from the chosing treatment for prostate cancer (choice) study","volume":"96","author":"Morgia","year":"2016","journal-title":"Urology"},{"issue":"10","key":"10.1016\/j.clgc.2023.07.003_bib0042","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1007\/s12325-018-0774-1","article-title":"Treatment duration, healthcare resource utilization, and costs among chemotherapy-na\u00efve patients with metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate: a retrospective claims analysis","volume":"35","author":"Schultz","year":"2018","journal-title":"Adv Ther"},{"issue":"5","key":"10.1016\/j.clgc.2023.07.003_bib0043","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1007\/s12325-020-01260-x","article-title":"Economic outcomes in patients with chemotherapy-na\u00efve metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate plus prednisone","volume":"37","author":"Ramaswamy","year":"2020","journal-title":"Adv Ther"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767323001702?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767323001702?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:37:29Z","timestamp":1761565049000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767323001702"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":43,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["S1558767323001702"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2023.07.003","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiovascular Adverse Events Associated With New-Generation Androgen Receptor Pathway Inhibitors (ARPI) for Prostate Cancer: A Disproportionality Analysis Based on the FDA Adverse Event Reporting System (FAERS)","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2023.07.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}